These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25826360)

  • 1. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
    Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
    Future Med Chem; 2015; 7(3):269-89. PubMed ID: 25826360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
    Thompson N; Lyons J
    Curr Opin Pharmacol; 2005 Aug; 5(4):350-6. PubMed ID: 15955734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
    Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors.
    Fu L; Chen S; He G; Chen Y; Liu B
    J Med Chem; 2022 Oct; 65(20):13561-13573. PubMed ID: 36205714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
    Li Q; Wu J; Zheng H; Liu K; Guo TL; Liu Y; Eblen ST; Grant S; Zhang S
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4526-30. PubMed ID: 20580230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
    Anders M; Christian C; McMahon M; McCormick F; Korn WM
    Cancer Res; 2003 May; 63(9):2088-95. PubMed ID: 12727824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.
    Polier G; Neumann J; Thuaud F; Ribeiro N; Gelhaus C; Schmidt H; Giaisi M; Köhler R; Müller WW; Proksch P; Leippe M; Janssen O; Désaubry L; Krammer PH; Li-Weber M
    Chem Biol; 2012 Sep; 19(9):1093-104. PubMed ID: 22999878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives on targeting RAF, MEK and ERK in melanoma.
    Dumaz N; Lebbé C
    Curr Opin Oncol; 2021 Mar; 33(2):120-126. PubMed ID: 33332926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
    Kidger AM; Sipthorp J; Cook SJ
    Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.